Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Margherita RiminiBernardo StefaniniToshifumi TadaGoki SudaShigeo ShimoseMasatoshi KudoFabian FinkelmeierChanghoon YooJosé PresaElisabeth AmadeoVirginia GenovesiMaria Caterina De GrandisMassimo IavaroneFabio MarraFrancesco FoschiEmiliano TamburiniFederico RossariFrancesco VitielloLinda BartaliniCaterina SoldàFrancesco TovoliCaterina VivaldiSara LonardiMarianna SillettaTakashi KumadaNaoya SakamotoHideki IwamotoTomoko AokiVera HimmelsbachMargarida MontesAtsushi HiraokaTakuya ShoTakashi NiizekiNaoshi NishidaChristoph SteupMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraTakeshi HatanakaSatoru KakizakiNoritomo ShimadaKazuhito KawataFujimasa TadaHideko OhamaKazuhiro NousoAkihiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiHisashi KosakaAtsushi NaganumaYohei KoizumiShinichiro NakamuraMasaki KaiboriHiroko IijimaYoichi HiasaMara PersanoSilvia CameraSilvia FotiLuca AldrighettiStefano CascinuAndrea Casadei-GardiniPiscaglia FabioPublished in: Liver international : official journal of the International Association for the Study of the Liver (2024)
Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.